Abraxane meets goal in pivotal Phase III trial in lung cancer
This article was originally published in Scrip
Executive Summary
Abraxis BioScience's chemotherapy Abraxane (protein-bound paclitaxel) has improved the primary response rate endpoint compared with standard Taxol (paclitaxel) when they were both combined with carboplatin in a registrational Phase III trial in first-line non-small cell lung cancer (NSCLC), leading to the company's shares to soar by 30% on Nasdaq on 17 March.